Drug Profile
Methoxsalen solution - Therakos
Alternative Names: Methoxsalen sterile solution - Therakos; UVADEXLatest Information Update: 20 Apr 2023
Price :
$50
*
At a glance
- Originator Therakos
- Developer Mallinckrodt Inc.; Therakos
- Class Antineoplastics; Antipsoriatics; Coumarins; Psoralens; Small molecules
- Mechanism of Action DNA cross linking agents; Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Cutaneous T-cell lymphoma
- Registered Graft-versus-host disease
Most Recent Events
- 30 Dec 2022 Mallinckrodt Pharmaceuticals has patent protection for Methoxsalen solution in USA and other countries
- 30 Dec 2022 Mallinckrodt Pharmaceuticals has patents pending for Methoxsalen solution in USA
- 07 Dec 2022 No development reported - Phase-III for Graft-versus-host disease (In adolescents, In children, In infants, In adults) in Germany, France (Extracorporeal) (NCT02524847)